Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Bioequivalence of two lithium formulations in healthy volunteers|
De Nucci, G
|Abstract:||Objective. The purpose of this study was to compare the maximum exposure and extent of bioavailability of two lithium carbonate (CAS 554-13-2) containing 300 mg tablet formulations (test and reference) for oral administration. Method. This bioequivalence study was conducted in a 2-period crossover design with a washout phase of 7 days. Plasma samples were obtained by blood sampling over 72 h in each period. Twenty-four healthy volunteers of both genders participated in the trial. Samples were analyzed by a flame atomic absorption spectrometer. Resulting Li+ concentrations were used for determination of the pharmacokinetic parameters AUC(last), AUC(inf) and C-max. Results: 90 % confidence intervals for AUC(last), AUC(inf), and C-max were 96.81-107.44 98.44-109.54 % and 98.60-111.33 respectively. Conclusion: All 90 % and 95 % confidence intervals were inside the limits defined by the FDA Guidance for Industry (80 %-125 %) and thus stated that test and reference formulation may be accepted as bioequivalent, with regard to both, maximum exposure and extent of bioavailability.|
lithium, bioavailability, bioequivalence
|Editor:||Ecv-editio Cantor Verlag Medizin Naturwissenschaften|
|Citation:||Arzneimittel-forschung-drug Research. Ecv-editio Cantor Verlag Medizin Naturwissenschaften, v. 56, n. 7, n. 524, n. 528, 2006.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.